Ignite Creation Date:
2025-12-25 @ 2:49 AM
Ignite Modification Date:
2026-03-11 @ 3:41 PM
Study NCT ID:
NCT02574533
Status:
COMPLETED
Last Update Posted:
2017-09-27
First Post:
2015-10-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
Sponsor:
Gradalis, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-10
Start Date Type:
ACTUAL
Primary Completion Date:
2017-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-09
Completion Date Type:
ACTUAL
First Submit Date:
2015-10-09
First Submit QC Date:
None
Study First Post Date:
2015-10-14
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-09-26
Last Update Post Date:
2017-09-27
Last Update Post Date Type:
ACTUAL